
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares Pa Shun Pharmaceutical International Holdings Limited (the “Company”), you should at once hand this circular and the accompanying proxy form to the purchaser(s) or transferee(s) or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



百信集團
PASHUN GROUP

Pa Shun Pharmaceutical International Holdings Limited

百信藥業國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 574)

PROPOSED DECLARATION OF FINAL DIVIDEND, GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING

A letter from the Board is set out on page 3 to 9 of this circular.

A notice dated 29 April 2016 convening an annual general meeting of the Company to be held at Sheraton Chengdu Lido Hotel, No. 15, Section 1, Ren Min Zhong Road, Qingyang District, Chengdu, Sichuan, PRC on Wednesday, 1 June 2016 at 2:30 p.m. is set out on pages 13 to 16 of this circular. Whether or not you intend to attend the meeting, you are requested to complete and return the enclosed form of proxy in accordance with the instructions printed thereon as soon as practicable and in any event not less than 48 hours before the time fixed for holding the annual general meeting (or any adjournment thereof) to the office of the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong. Completion and return of the form of proxy will not preclude you from attending and voting in person at the annual general meeting and any adjourned meeting if you so wish and in such event, the instrument appointing a proxy shall be deemed to be revoked.

29 April 2016

TABLE OF CONTENTS

	<i>Page</i>
Definitions	1
Letter from the Board	3
Appendix – Explanatory Statement	10
Notice of Annual General Meeting	13

DEFINITIONS

In this circular, the following expressions have the following meanings, unless the context requires otherwise:

“AGM”	the annual general meeting of the Company to be convened on Wednesday, 1 June 2016, at 2:30 p.m. at Sheraton Chengdu Lido Hotel, No. 15, Section 1, Ren Min Zhong Road, Qingyang District, Chengdu, Sichuan, PRC;
“Articles of Association”	the articles of association of the Company;
“associate(s)”	has the meaning ascribed to this term under the Listing Rules;
“Board”	the board of Directors;
“Company”	Pa Shun Pharmaceutical International Holdings Limited 百信藥業國際控股有限公司, a company incorporated in the Cayman Islands with limited liability with its securities listed on the Stock Exchange;
“Directors”	directors of the Company;
“Group”	the Company and its subsidiaries;
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong;
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China;
“Issue Mandate”	the general mandate proposed to be granted to the Directors at the AGM to issue, allot and deal with up to 20% of the issued share capital of the Company as set out in the paragraph headed “Letter from the Board – General Mandates ” of this circular;
“Latest Practicable Date”	21 April 2016, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein;
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange;

DEFINITIONS

“Repurchase Mandate”	the general mandate proposed to be granted to the Directors at the AGM to repurchase up to 10% of the issued share capital of the Company as set out in the paragraph headed “Letter from the Board – General Mandates” of this circular;
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong);
“Share(s)”	the ordinary share(s) of HK\$0.001 each in the share capital of the Company;
“Shareholder(s)”	the shareholders of the Company from time to time; and
“Stock Exchange”	The Stock Exchange of Hong Kong Limited.

LETTER FROM THE BOARD



百信集團
PASHUN GROUP

Pa Shun Pharmaceutical International Holdings Limited
百信藥業國際控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 574)

Executive directors:

Mr. Chen Yenfei (*Chairman*)
Mr. Shen Shun
Mr. Zhou Jian

Non-executive directors:

Mr. Li Ho Tan
Mr. Masahiro Honna

Independent non-executive directors:

Mr. Liu Liangzhong
Mr. Wong Tak Shing
Mr. Min Feng

Registered office:

Cricket Square
Hutchins Drive
P. O. Box 2681
Grand Cayman KY1-1111
Cayman Islands

*Principal place of business in
Hong Kong:*

Flat 1907B
19/F., Hopewell Centre
183 Queen's Road East
Wanchai, Hong Kong

29 April 2016

To Shareholders

Dear Sir or Madam,

**PROPOSED DECLARATION OF FINAL DIVIDEND,
GENERAL MANDATES TO ISSUE AND
REPURCHASE SHARES, RE-ELECTION OF DIRECTORS
AND
NOTICE OF ANNUAL GENERAL MEETING**

INTRODUCTION

The purpose of this circular is to provide you with information in respect of the resolutions to be proposed at the AGM relating to (i) the proposed declaration of final dividend; (ii) the granting to the Directors a general mandate to allot, issue and deal with Shares not exceeding 20% of the Shares in the issued share capital of the Company as at the date of resolution; (iii) the granting to the Directors a general mandate to repurchase the Shares not exceeding 10% of the Shares in the issued share capital of the Company as at the date of resolution; and (iv) the re-election of retiring Directors.

LETTER FROM THE BOARD

DECLARATION OF FINAL DIVIDEND

According to the announcement of the annual results of the Company for the year ended 31 December 2015 dated 31 March 2016, the Board has recommended a final dividend of HK3.0 cents per Share payable to the Shareholders whose names appear on the register of members of the Company on Friday, 10 June 2016. Subject to the Shareholders' approval at the AGM, the proposed final dividend will be distributed on Tuesday, 5 July 2016.

GENERAL MANDATES

At the AGM, separate ordinary resolutions will be proposed to grant the general mandates to the Directors (i) to allot, issue and otherwise deal with Shares not exceeding in aggregate 20% of the aggregate nominal amount of the issued share capital of the Company at the date of the passing of such resolution (the "Issue Mandate"); (ii) to repurchase issued and fully paid Shares on the Stock Exchange up to a maximum of 10% of the aggregate nominal amount of the issued share capital of the Company at the date of passing of such resolution (the "Repurchase Mandate"); and to add the aggregate amount of the Shares repurchased by the Company to the Issue Mandate.

As at the Latest Practicable Date, there were in aggregate 1,000,000,000 Shares in issue. Subject to the passing of the proposed resolutions for the grant of the Issue Mandate and the Repurchase Mandate, and on the basis that no further Shares will be issued or repurchased prior to the date of the AGM, exercise in full of the Repurchase Mandate will result in up to 100,000,000 Shares being repurchased by the Company, and the Directors will be authorised to allot and issue under the Issue Mandate up to 200,000,000 Shares, and to the extent the Repurchase Mandate is exercised, plus the amount of Shares representing the aggregate nominal amount of the share capital of the Company repurchased by the Company under the Repurchase Mandate.

The Issue Mandate and the Repurchase Mandate shall continue in force during the period ending on the earliest of (a) the date of the next annual general meeting; (b) the date by which the next annual general meeting of the Company is required to be held by law or by its Articles of Association; or (c) the date upon which such authority is revoked or varied by an ordinary resolution of the Shareholders in a general meeting of the Company.

Under the Listing Rules, the Company is required to give to the Shareholders all information which is reasonably necessary to enable the Shareholders to make an informed decision as to whether to vote for or against the resolution to renew the grant to the Directors of the Repurchase Mandate. The explanatory statement required by the Listing Rules to be included in this circular is set out in the Appendix to this circular.

LETTER FROM THE BOARD

RE-ELECTION OF DIRECTORS

Pursuant to Article 84 of the Articles of Association, at each annual general meeting of the Company, one-third of the Directors for the time being (or, if their number is not three or a multiple of three (3), the number nearest to but not less than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement by rotation at least once every three years. Any Director who has not been subject to retirement by rotation in the three years preceding the annual general meeting shall retire by rotation at such annual general meeting. The Directors to retire by rotation shall include any Director who wishes to retire and not to offer himself for re-election. Any further Directors so to retire shall be those of the other Directors subject to retirement by rotation who have been longest in office since their last re-election or appointment and so that as between persons who became or were last re-elected Directors on the same day those to retire shall (unless they otherwise agree among themselves) be determined by lot.

Accordingly, the Directors retiring by rotation at the AGM are Mr. Chen Yenfei, Mr. Shen Shun and Mr. Zhou Jian, who being eligible, offer themselves for re-election at the forthcoming AGM.

The biographical details of all the retiring Directors as follows:

EXECUTIVE DIRECTORS

CHEN YENFEI, or CHEN YEN FEI, (陳燕飛), aged 68, was appointed as our executive Director on 3 May 2011. He is the founder of the Group, the chairman of the Board and the chief executive officer. He is mainly responsible for the overall business management and strategic planning of our Group. Mr. Chen has approximately 30 years of experience in the pharmaceutical industry. He has been the chairman of Chengdu Toyot Pa Shun Pharmacy Co., Ltd.* (成都東洋百信製藥有限公司) since 1995, and has been the chairman of Toyot Pa Shun Medicine Factory Company Limited (東洋百信製藥廠有限公司) since 1989. Mr. Chen graduated from Zhongnan University of Economics* (中南財經大學) (predecessor of Zhongnan University of Economics and Law (中南財經政法大學)) with a bachelor degree in July 1987, majoring in statistics and Hubei Traditional Chinese Medical Science College* (湖北中醫學院) (predecessor of Hubei University of Chinese Medicine (湖北中醫藥大學)) in June 1998, majoring in traditional Chinese medicine, respectively. Mr. Chen also was elected as one of members of the first session of standing committee of China Association of Traditional Chinese Medicine* (中國中藥協會). He was the vice-president of Wuhan Pharmaceutical Profession Association* (武漢醫藥行業協會) in 2003, vice-president of Hubei Guangcai Association* (湖北光彩學會) since 2006 and the executive committee vice chairman of Hong Kong Chamber of Commerce in China-Wuhan (中國香港地區商會－武漢) since 2010, respectively.

LETTER FROM THE BOARD

SHEN SHUN (沈順), aged 43, was appointed as an executive Director of the Company on 27 February 2012. Mr. Shen is mainly responsible for sales and internal control. He has about 15 years of experience in the pharmaceutical industry. Mr. Shen has been appointed as a vice general manager of Chengdu Kexun Pharmacy Co., Ltd* (成都科訊藥業有限公司) (“Chengdu Kexun”) since 1998, responsible for sales. Mr. Shen obtained a master degree of business administration from a course jointly cooperated by Southwest Jiaotong University* (西南交通大學) and University of South Australia in May 2011. He graduated from Southwest Jiaotong University* (西南交通大學), majoring in business administration in June 2006 by long-distance online education* (網絡教育學院).

ZHOU JIAN (周建), aged 59, was appointed as an executive Director of the Company on 27 February 2012. Mr. Zhou is mainly responsible for medicines supply and internal control. He has over 30 years of experience in the pharmaceutical industry. Mr. Zhou has been appointed as the general manager of Chengdu Kexun since 1999, responsible for purchase and sale business and overall management. Prior to joining the Group, Mr. Zhou worked for Shenzhen Hua Chen Pharmaceuticals Co., Ltd* (深圳華辰藥業有限公司) as a manager from 1991 to 1998, responsible for management and operation of the company. He also worked for Chongqing Yong Zhou Chinese Herbal Medicine Company* (重慶市永州區中藥材公司) as an assistant manager from 1979 to 1991, responsible for purchase and sale business. Mr. Zhou graduated from Yuzhou University* (渝州大學) in February 1992, majoring in enterprise management. In addition, Mr. Zhou obtained the qualification of economist in entrepreneurial management* (企業管理經濟師) granted by Qualification Evaluation Committee of Intermediate-level Profession of the China National Group Corporation of Traditional and Herbal Medicine* (中國藥材公司中級專業技術職務評審委員會) in November 1996.

Each of Mr. Chen Yenfei, Mr. Shen Shun and Mr. Zhou Jian and the Company entered into a service contract on 26 May 2015. The term of their respective appointment was for an initial term of three years commencing from 19 June 2015. Such service contracts may be terminated by not less than one month’s notice in writing served by either party on the other. Each of Mr. Chen Yenfei, Mr. Shen Shun and Mr. Zhou Jian is entitled to a basic remuneration and a bonus as determined by the Board based on the recommendations made by the remuneration committee of the Board. The emoluments of each of these Directors have been determined by the Board with reference to his experience, duties, responsibilities, the results of the Group as well as prevailing market conditions. For the year ended 31 December 2015, each of Mr. Chen Yenfei, Mr. Shen Shun and Mr. Zhou Jian received remuneration plus bonus and other benefits of RMB392,000, RMB864,000 and RMB174,000, respectively.

LETTER FROM THE BOARD

As at the Latest Practicable Date, each of Chen Yenfei, Mr. Shen Shun and Mr. Zhou Jian had interests in the Shares as follows:

Number and percentage of Shares

Mr. Chen Yenfei	488,040,000 (48.80%) <i>(note 1)</i>
Mr. Shen Shun	Nil (0.00%)
Mr. Zhou Jian	Nil (0.00%)

Notes:

1. Mr. Chen Yenfei holds 100% of the issued share capital of Praise Treasure Limited and is therefore deemed to be interested in the 488,040,000 Shares held by Praise Treasure Limited.

Save as disclosed hereof, as at the Latest Practicable Date, and to the best knowledge and belief of the Board, the Directors confirmed that:

- (a) each of Mr. Chen Yenfei, Mr. Shen Shun and Mr. Zhou Jian is not connected with any Director, senior management, substantial Shareholder or controlling Shareholder of the Company;
- (b) each of Mr. Chen Yenfei, Mr. Shen Shun and Mr. Zhou Jian has no other interests in the Shares which are required to be disclosed under Part XV of the SFO;
- (c) each of Mr. Chen Yenfei, Mr. Shen Shun and Mr. Zhou Jian does not hold any directorships in other listed public companies in the last three years;
- (d) there is no other information that needs to be disclosed pursuant to any of the requirements as set out in Rule 13.51(2)(h) to (v) of the Listing Rules; and
- (e) the Company is not aware of any other matter that needs to be brought to the attention of the Shareholders and the Stock Exchange in relation to the re-election of Directors.

LETTER FROM THE BOARD

CLOSURE OF REGISTER OF MEMBERS

The register of members of the Company will be closed from Monday, 30 May 2016 to Wednesday, 1 June 2016 (both days inclusive), during which period no transfer of shares of the Company will be registered. In order to determine the identity of the Shareholders who are entitled to attend and vote at the AGM, all share transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong for registration not later than 4:30 p.m. on Friday, 27 May 2016.

In addition, the register of members of the Company will be closed from Wednesday, 8 June 2016 to Friday, 10 June 2016 (both days inclusive) for the purpose of ascertaining Shareholders' entitlement to the proposed final dividend. In order to determine the identity of the Shareholders who are entitled to the proposed final dividend, all share transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong for registration not later than 4:30 p.m. on Tuesday, 7 June 2016.

THE AGM, PROXY ARRANGEMENT AND DEMAND FOR POLL

A notice convening the AGM to be held on Wednesday, 1 June 2016, at 2:30 p.m. at Sheraton Chengdu Lido Hotel, No. 15, Section 1, Ren Min Zhong Road, Qingyang District, Chengdu, Sichuan, PRC is set out on pages 13 to 16 of this circular.

A form of proxy for use at the AGM is enclosed with this circular. Whether or not you are able to attend the AGM, you are requested to complete and return the accompanying form of proxy in accordance with the instructions printed thereon as soon as possible and in any event not less than 48 hours before the time appointed for the holding of the AGM (or any adjournment thereof) to the office of the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish and in such event, the instrument appointing a proxy shall be deemed to be revoked.

Pursuant to rule 13.39(4) of the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll except where the chairman of the general meeting, in good faith, decides to allow a resolution which relates purely to procedural or administrative matter to be voted by a show of hands. Accordingly, each of the resolutions put to vote at the AGM will be taken by way of poll.

LETTER FROM THE BOARD

The Directors are not aware of any Shareholders who are required to abstain from voting in the AGM. An announcement on the poll results will be published by the Company after the AGM in the manner prescribed under rule 13.39(5) of the Listing Rules.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Group. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

RECOMMENDATION

The Directors consider that all the proposed resolutions at the AGM are in the interests of the Company and the Shareholders as a whole and, accordingly, the Directors recommend all Shareholders to vote in favour of all the resolutions to be proposed at the AGM in respect thereof.

Yours faithfully

By order of the Board of Directors

Pa Shun Pharmaceutical International Holdings Limited

Mr. Chen Yenfei

Chairman

This Appendix serves as an explanatory statement given to all the Shareholders, as required by the Listing Rules, to provide all the requisite information in relation to the Repurchase Mandate.

1. LISTING RULES RELATING TO THE REPURCHASES OF SECURITIES

The Listing Rules permit companies whose primary listing is on the Stock Exchange to repurchase their fully-paid shares on the Stock Exchange subject to certain restrictions, the more important of which are summarised below:

(a) Shareholders' approval

All proposed purchase of securities on the Stock Exchange by a company with its primary listing on the Stock Exchange must be approved in advance by the shareholders by an ordinary resolution, either by way of a general mandate or by a specific approval in relation to a specific transaction.

(b) Share capital

Under the Repurchase Mandate, the number of Shares that the Company may repurchase shall not exceed 10% of the aggregate nominal amount of its issued share capital at the date of the passing of the proposed resolution granting the Repurchase Mandate.

As at the Latest Practicable Date, the Company had 1,000,000,000 Shares in issue. Subject to the passing of the proposed resolution for the grant of the Repurchase Mandate and on the basis that no Shares are issued or repurchased by the Company prior to the AGM, the exercise of the Repurchase Mandate in full would result in up to 100,000,000 Shares being repurchased by the Company.

(c) Reason for repurchase

The Directors believe that it is in the interests of the Company and the Shareholders to have a general authority from the Shareholders to enable the Directors to repurchase securities of the Company on the market. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net assets and/or its earnings per Share of the Company and will only be made when the Directors believe that such repurchases will benefit the Company and the Shareholders.

(d) Fund of repurchase

In repurchasing securities, a company may only apply funds legally available for such purpose in accordance with its constitutive documents and the laws of the Cayman Islands, being the jurisdiction in which the Company was incorporated.

As compared with the financial position of the Company as at 31 December 2015 (being the date of its latest audited accounts), the Directors consider that there would not be a material adverse impact on the working capital or gearing position of the Company if the Repurchase Mandate was to be exercised in full during the proposed repurchase period. However, the Directors do not propose to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital or the gearing level (as compared with the position disclosed in its most recent published audited accounts) which in the opinion of the Directors are from time to time appropriate for the Company.

(e) Connected parties

None of the Directors nor, to the best knowledge having made all reasonable enquiries, any of their respective close associates (as defined in the Listing Rules) has any present intention to sell Shares to the Company if the Repurchase Mandate is approved by the Shareholders. As at the Latest Practicable Date, no core connected person (as defined in the Listing Rules) had notified the Company that he has a present intention to sell Shares to the Company, or has undertaken not to do so, if the Repurchase Mandate is approved by the Shareholders.

(f) Undertaking by Directors

The Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the Repurchase Mandate in accordance with the Listing Rules and the applicable laws of the Cayman Islands.

(g) Takeovers Code

If as a result of a securities repurchase, a Shareholder's proportionate interest in the voting rights of the repurchasing company increases, such increase will be treated as an acquisition of voting rights for the purpose of the Hong Kong Code on Takeovers and Mergers (the "Takeovers Code").

As at the Latest Practicable Date, Mr. Chen Yenfei, together with his respective associates, were beneficially interested in 488,040,000 Shares, representing approximately 48.80% of the issued Shares. In the event that the Directors exercise the Repurchase Mandate in full in accordance with the terms of the ordinary resolution to be proposed at the AGM, the interests of the substantial Shareholders, together with their respective associates, in the Company would be increased to approximately 54.23% of the issued Shares, which will give rise to an obligation to make a mandatory offer under Rules 26 and 32 of the Takeovers Code. However, the Directors have no present intention to exercise the power to repurchase the Shares pursuant to the Repurchase Mandate to such an extent as to result in mandatory offer obligations.

(h) Public float

The Directors confirm that the Repurchase Mandate will not be exercised to an extent where the amount of Shares held by the public will be reduced below 25%.

2. SHARE PURCHASE MADE BY THE COMPANY

During six months preceding the date of this circular, no Shares have been repurchased by the Company.

3. SHARE PRICES

During each of the 11 months since 19 June 2015, being the date of listing of Shares on the Stock Exchange up to the Latest Practicable Date, the highest and lowest traded prices for Shares on the Stock Exchange were as follows:

Month	Price Per Share	
	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
2015		
June	2.48	1.19
July	2.10	0.60
August	1.17	0.70
September	0.96	0.77
October	1.20	0.79
November	0.98	0.82
December	1.02	0.82
2016		
January	0.86	0.65
February	0.68	0.54
March	0.68	0.50
April (up to the Latest Practicable Date)	0.67	0.58

NOTICE OF ANNUAL GENERAL MEETING



百信集團
PASHUN GROUP

Pa Shun Pharmaceutical International Holdings Limited

百信藥業國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 574)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the annual general meeting of Pa Shun Pharmaceutical International Holdings Limited (the “Company”) will be held on Wednesday, 1 June 2016, at 2:30 p.m. at Sheraton Chengdu Lido Hotel, No. 15, Section 1, Ren Min Zhong Road, Qingyang District, Chengdu, Sichuan, PRC for the following purposes:

1. To receive and approve the audited consolidated financial statements, the reports of the directors and independent auditor for the year ended 31 December 2015.
2. (A) To re-elect Mr. Chen Yenfei as a director of the Company (the “Director”).
(B) To re-elect Mr. Shen Shun as the Director.
(C) To re-elect Mr. Zhou Jian as the Director.
3. To authorise the board to fix the remuneration of the Directors.
4. To re-appoint Crowe Horwath (HK) CPA Limited as auditor and to authorise the Directors to fix the remuneration of the auditor.
5. To declare a final dividend of HK3.00 cents per share of the Company for the year ended 31 December 2015 to the shareholders of the Company.

SPECIAL BUSINESS

6. As special business to consider and, if thought fit, pass with or without modifications, each of the following resolutions as an ordinary resolution of the Company:

ORDINARY RESOLUTIONS

- (A) **“THAT**
 - (a) subject to paragraph (c) of this Resolution, the exercise by the Directors during the Relevant Period (as defined below) of all the powers of the Company to allot, issue and deal with additional shares in the capital of the Company and to make or grant offers, agreements and options which might require the exercise of such powers be and is hereby generally and unconditionally approved;

NOTICE OF ANNUAL GENERAL MEETING

- (b) the approval in paragraph (a) of this Resolution shall authorise the Directors during the Relevant Period to make or grant offers, agreements and options which might require the exercise of such powers after the end of the Relevant Period;
- (c) the aggregate nominal amount of share capital allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) by the Directors pursuant to the approval in paragraph (a) of this Resolution, otherwise than pursuant to (i) a Rights Issue (as defined below); (ii) the exercise of rights of subscription or conversion under the terms of any warrants issued by the Company or any securities which are convertible into shares of the Company; (iii) the exercise of any option under any share option scheme or similar arrangement for the time being adopted for the grant or issue to officers, employees of the Company and/or any of its subsidiaries or other eligible participants of shares or rights to acquire shares in the Company; or (iv) any scrip dividend or similar arrangement providing for the allotment of shares in lieu of the whole or part of the cash payment for a dividend on shares of the Company in accordance with the articles of association of the Company, shall not exceed 20% of the aggregate nominal amount of the share capital of the Company in issue at the date of this Resolution and the said approval shall be limited accordingly; and
- (d) for the purposes of this Resolution:

“**Relevant Period**” means the period from the passing of this Resolution until whichever is the earlier of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable law to be held; and
- (iii) the date of which the authority set out in this Resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.

NOTICE OF ANNUAL GENERAL MEETING

“**Rights Issue**” means an offer of shares or other securities of the Company open for a period fixed by the Directors to holders of shares of the Company or any class thereof on the register on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusion or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognized regulatory body or any stock exchange in, any territory outside the Hong Kong Special Administrative Region of the People’s Republic of China).”

(B) “**THAT**

- (a) subject to paragraph (b) of this Resolution, the exercise by the Directors during the Relevant Period (as defined below) of all powers of the Company to repurchase shares of the Company, subject to and in accordance with all applicable laws and requirements, be and is hereby generally and unconditionally approved;
- (b) the aggregate nominal amount of the shares of the Company which may be purchased pursuant to the approval in paragraph (a) of this Resolution shall not exceed 10% of the aggregate nominal amount of the share capital of the Company as at the date of passing of this Resolution and the said approval shall be limited accordingly; and
- (c) for the purposes of this resolution:

“**Relevant Period**” means the period from the passing of this Resolution until whichever is the earlier of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable law to be held; and
- (iii) the date which the authority set out in this Resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.”

NOTICE OF ANNUAL GENERAL MEETING

- (C) “**THAT** conditional upon Resolutions 6(A) and 6(B) set out above being passed, the aggregate nominal amount of the shares of the Company which are repurchased by the Company under the authority granted to the Directors as mentioned in Resolution 6(B) above shall be added to the aggregate nominal amount of the share capital of the Company that may be allotted or agreed conditionally or unconditionally to be allotted by the Directors pursuant to the Resolution 6(A) above.”

By order of the Board
Pa Shun Pharmaceutical International Holdings Limited
Mr. Chen Yenfei
Chairman

Hong Kong, 29 April 2016

Notes:

1. Any shareholder entitled to attend and vote at the meeting is entitled to appoint one or, if he is holder of more than one share, more proxies to attend and vote instead of him. A proxy need not be a shareholder of the Company.
2. In order to be valid, a form of proxy in the prescribed form together with the power of attorney or other authority (if any) under which it is signed must be deposited at the branch share registrar of the Company, Tricor Investor Services Limited, Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong not less than 48 hours before the time appointed for holding the meeting (or any adjournment thereof).
3. The instrument appointing a proxy shall be in writing under the hand of the appointor or of his attorney duly authorised in writing or, if the appointor is a corporation, either under its common seal or under the hand of an officer or attorney or other person duly authorised.
4. Delivery of the form of proxy will not preclude a member from attending and voting in person at the meeting convened and in such event, the form of proxy shall be deemed to be revoked.